Compare · AXGN vs LHDX
AXGN vs LHDX
Side-by-side comparison of Axogen Inc. (AXGN) and Lucira Health Inc. (LHDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and LHDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.04B, about 9.9x LHDX ($206.3M).
- AXGN has hit the wire 2 times in the past 4 weeks while LHDX has been quiet.
- AXGN has more recent analyst coverage (8 ratings vs 0 for LHDX).
- Company
- Axogen Inc.
- Lucira Health Inc.
- Price
- $39.26+4.83%
- $0.45-19.60%
- Market cap
- $2.04B
- $206.3M
- 1M return
- +17.97%
- -
- 1Y return
- +142.80%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 2
- 0
- Recent ratings
- 8
- 0
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Lucira Health Inc.
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
Latest AXGN
- CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
- Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Axogen Inc.
- SEC Form 4 filed by Devinney Erick Wayne
- SEC Form 4 filed by Hartley Lindsey Marie
- Chief Marketing Officer Kemp Jens was granted 50,670 shares and covered exercise/tax liability with 18,366 shares, increasing direct ownership by 73% to 76,451 units (SEC Form 4)
- Chief Innovation Officer Devinney Erick Wayne was granted 33,780 shares and covered exercise/tax liability with 21,978 shares, increasing direct ownership by 5% to 252,934 units (SEC Form 4)
- EVP & General Counsel Began Marc A converted options into 11,250 shares, was granted 33,780 shares and covered exercise/tax liability with 13,180 shares, increasing direct ownership by 174% to 50,135 units (SEC Form 4)
- CFO Hartley Lindsey Marie was granted 17,453 shares and covered exercise/tax liability with 6,630 shares, increasing direct ownership by 24% to 55,276 units (SEC Form 4)
- SEC Form 4 filed by Chief Executive Officer Dale Michael D
Latest LHDX
- SEC Form 15-12G filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Other Events, Bankruptcy or Receivership
- SEC Form NT 10-Q filed by Lucira Health Inc.
- SEC Form S-8 POS filed by Lucira Health Inc.
- SEC Form S-8 POS filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form NT 10-Q filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits
- Lucira Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form NT 10-K filed by Lucira Health Inc.